Aldeyra Therapeutics Investor Relations Material

Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company is engaged in advancing its pipeline of drug candidates, which target diseases caused by inflammation and tissue damage. Aldeyra's approach is centered on modulating immune responses to treat conditions such as ocular and systemic inflammatory diseases. Its lead therapeutic areas include ophthalmology, with treatments aimed at conditions like dry eye disease and allergic conjunctivitis. The company's goal is to provide new treatment options for diseases with limited or inadequate therapies. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.